Mitsubishi UFJ Trust & Banking Corp Trims Stock Position in Sana Biotechnology, Inc. (NASDAQ:SANA)

Mitsubishi UFJ Trust & Banking Corp lowered its position in shares of Sana Biotechnology, Inc. (NASDAQ:SANAGet Rating) by 2.0% in the 2nd quarter, Holdings Channel.com reports. The fund owned 243,980 shares of the company’s stock after selling 4,910 shares during the period. Mitsubishi UFJ Trust & Banking Corp’s holdings in Sana Biotechnology were worth $1,569,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. National Bank of Canada FI grew its stake in Sana Biotechnology by 2,162.2% during the second quarter. National Bank of Canada FI now owns 4,185 shares of the company’s stock valued at $27,000 after acquiring an additional 4,000 shares in the last quarter. XTX Topco Ltd purchased a new position in Sana Biotechnology in the 1st quarter worth approximately $86,000. Hsbc Holdings PLC purchased a new position in Sana Biotechnology in the 1st quarter worth approximately $90,000. Arizona State Retirement System grew its stake in Sana Biotechnology by 125.6% in the 2nd quarter. Arizona State Retirement System now owns 23,028 shares of the company’s stock worth $148,000 after buying an additional 12,819 shares in the last quarter. Finally, E Fund Management Co. Ltd. purchased a new position in Sana Biotechnology in the 1st quarter worth approximately $201,000. Hedge funds and other institutional investors own 64.49% of the company’s stock.

Analyst Ratings Changes

Separately, The Goldman Sachs Group cut their price target on shares of Sana Biotechnology from $7.00 to $6.00 and set a “neutral” rating for the company in a research note on Thursday, November 3rd.

Sana Biotechnology Stock Performance

Shares of SANA opened at $4.76 on Monday. The firm has a market cap of $907.86 million, a price-to-earnings ratio of -2.96 and a beta of 0.41. Sana Biotechnology, Inc. has a fifty-two week low of $3.92 and a fifty-two week high of $21.72. The firm has a 50 day moving average price of $5.74 and a 200-day moving average price of $6.23.

Sana Biotechnology Company Profile

(Get Rating)

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others.

Featured Stories

Want to see what other hedge funds are holding SANA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sana Biotechnology, Inc. (NASDAQ:SANAGet Rating).

Institutional Ownership by Quarter for Sana Biotechnology (NASDAQ:SANA)

Receive News & Ratings for Sana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sana Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.